SCHEMBL4071355

SCHEMBL4071355

Cn1cc2c(cc1=O)C1(CCN(Cc3ccc(C(=NOCC(C)(C)O)c4ccc(Cl)cn4)cc3)CC1)OC2

nearest known ligand 0.71

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 12/20 0.71
KCNH2 Q12809 11/20 0.71
PRCP P42785 1/20 0.33
F10 P00742 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
AVPR1A P37288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071349 1.00 MCHR1 (0.71) MCHR1KCNH2PRCPF10SIGMAR1
SCHEMBL4075478 0.90 MCHR1 (0.86) MCHR1KCNH2
SCHEMBL4065643 0.90 MCHR1 (0.86) MCHR1KCNH2
SCHEMBL4065636 0.90 MCHR1 (0.86) MCHR1KCNH2
SCHEMBL13664946 0.84 MCHR1 (0.64) MCHR1KCNH2F10SIGMAR1
SCHEMBL4066961 0.83 MCHR1 (1.00) MCHR1KCNH2
SCHEMBL4068858 0.83 MCHR1 (1.00) MCHR1KCNH2
SCHEMBL4066972 0.83 MCHR1 (1.00) MCHR1KCNH2
SCHEMBL4067114 0.82 MCHR1 (0.89) MCHR1KCNH2
SCHEMBL4067107 0.82 MCHR1 (0.89) MCHR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US claimed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP claimed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247560-A1 Diaryl ketimine derivative NR0B2, NR2C2, NR3C2 MCHR1 730/4885KCNH2 296/4885PRCP 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.